Gain of Chromosome 5q Predicts a Favorable Prognosis in Localized Renal Cell Carcinoma

By sjmartinez • February 6, 2024

Lebacle C, Pooli A, Shuch B, Rao N, Chamie K, Kroeger N, Faiena I, Liu S, Wood EL, Belldegrun A, Drakaki A, Pantuck AJ. Gain of Chromosome 5q Predicts a Favorable Prognosis in Localized Renal Cell Carcinoma. Cancer Invest. 2024 Feb 5:1-7. doi: 10.1080/07357907.2024.2308172. Epub ahead of print. PMID: 38314786.

Tags: 5q chromosome, adjuvant treatment, cytogenetic, Fellow, follow-up, Hematology/Oncology, Publications, Renal cell carcinoma

Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer

Silverstein J, Alomaja O, Chatram D, Hajiabbasi M, Shachar E, Tseng CH, Thaker S, Bardia A, Karlan B, Hendrickson AW, Konecny GE. Real-world clinical outcomes[...]

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial

Falchi L, Offner F, de Vos S, Brody JD, Morillo D, Linton K, Snauwaert S, Roost Clausen M, Karimi YH, Thieblemont C, Vitolo U, Leslie[...]

Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial

Saba NF, Posner M, Harrington K, Neupane P, Rezaee R, Nenclares P, Jimeno A, Denker AE, MacIntyre S, Makris L, Wong D. Danvatirsen plus pembrolizumab[...]